Business Week January 15 By Aaron PressmanAs Barack Obama closed in on the Presidency last year, investors got increasingly skittish about drug stocks. Johnson & Johnson fell 18% in the two months before the election, Schering-Plough dropped 23%, and Eli Lilly tumbled 28%. Investors had good reason to be worried. Obama’s health-care reform plan is likely to include letting Medicare negotiate lower drug prices, overturning a ban on government-driven discounts that was in the original 2003 “Part D” program.
...
THE NEW DRILL FOR PHARMALOWER PRICES
Republican authors of the 2003 Medicare drug plan barred the government from negotiating discounts. Obama and congressional Democrats will overturn the ban, reducing prices paid for drugs. All major pharma players may be affected.
NEW LEADERSHIP
Critics of the Food & Drug Administration say few drugs of consequence have been approved over the past few years and that the FDA shied away from anything controversial. New leadership could change that.
BIOTECH GENERICS
Congress plans to create a procedure to allow generic copies of treatments by biotech companies. That may cut into profi ts at some drug developers, but generic makers will expand their market share.